Repligen Co. (NASDAQ:RGEN) Given Average Rating of “Moderate Buy” by Analysts

Repligen Co. (NASDAQ:RGEN) has received an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $194.00.

A number of analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, Guggenheim assumed coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating for the company.

Repligen Trading Up 0.7 %

Shares of Repligen stock opened at $132.36 on Friday. The company has a fifty day simple moving average of $136.09 and a 200-day simple moving average of $166.88. Repligen has a 12-month low of $110.45 and a 12-month high of $211.13. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.40 billion, a price-to-earnings ratio of 529.46, a PEG ratio of 4.44 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 EPS. On average, equities analysts forecast that Repligen will post 1.46 EPS for the current fiscal year.

Insider Activity

In other news, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, Director Martin D. Madaus bought 1,615 shares of the company’s stock in a transaction on Friday, June 14th. The stock was purchased at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the acquisition, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently added to or reduced their stakes in RGEN. Bank of New York Mellon Corp grew its holdings in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after buying an additional 237,884 shares in the last quarter. EFG Asset Management North America Corp. grew its holdings in shares of Repligen by 23.8% during the second quarter. EFG Asset Management North America Corp. now owns 24,824 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 4,765 shares in the last quarter. IMA Advisory Services Inc. purchased a new stake in shares of Repligen during the second quarter worth about $1,066,000. Bank Pictet & Cie Europe AG grew its holdings in shares of Repligen by 44.9% during the second quarter. Bank Pictet & Cie Europe AG now owns 2,144 shares of the biotechnology company’s stock worth $270,000 after buying an additional 664 shares in the last quarter. Finally, Banque Pictet & Cie SA grew its holdings in shares of Repligen by 74.6% during the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock worth $4,351,000 after buying an additional 14,746 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.